Trial Profile
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product (IMC-1121B) versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction, or Stomach
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jan 2020
Price :
$35
*
At a glance
- Drugs Ramucirumab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 01 Dec 2019 Results assessing addition of ramucirumab to front-line mFOLFOX6 were published in the Annals of Oncology
- 20 Oct 2016 Results published in the Annals of Oncology
- 03 Jul 2014 Planned number of patients changed from 166 to 162.